Aby J. Mathew Sells 7,604 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 7,604 shares of the business’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $27.33, for a total transaction of $207,817.32. Following the completion of the sale, the executive vice president now owns 276,315 shares of the company’s stock, valued at $7,551,688.95. The trade was a 2.68 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

BioLife Solutions Stock Performance

BioLife Solutions stock traded up $1.13 during trading hours on Thursday, hitting $26.11. The stock had a trading volume of 404,267 shares, compared to its average volume of 384,028. The company has a 50-day moving average of $24.78 and a two-hundred day moving average of $23.66. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a fifty-two week low of $14.50 and a fifty-two week high of $28.88. The company has a market cap of $1.21 billion, a PE ratio of -24.63 and a beta of 1.91.

Analysts Set New Price Targets

BLFS has been the subject of a number of research analyst reports. Benchmark reissued a “buy” rating and set a $30.00 target price on shares of BioLife Solutions in a research report on Thursday. Craig Hallum boosted their price objective on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. HC Wainwright decreased their target price on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research note on Monday, November 18th. TD Cowen lifted their price target on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, KeyCorp increased their price objective on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $29.00.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Mark Sheptoff Financial Planning LLC acquired a new stake in BioLife Solutions during the third quarter worth $28,000. 1620 Investment Advisors Inc. acquired a new position in shares of BioLife Solutions in the 2nd quarter valued at $35,000. Quest Partners LLC bought a new position in shares of BioLife Solutions during the 3rd quarter worth about $57,000. GAMMA Investing LLC boosted its position in shares of BioLife Solutions by 29.4% during the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after acquiring an additional 748 shares in the last quarter. Finally, Canada Pension Plan Investment Board bought a new stake in BioLife Solutions in the second quarter valued at about $122,000. 93.24% of the stock is currently owned by institutional investors and hedge funds.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.